Frazier backs $50M series B for Dascena’s disease prediction algorithms

With both real-world evidence and clinical trial data supporting its sepsis prediction algorithm, Dascena has raised a $50 million series B to expand the system into more hospitals, and also move forward its next program in acute kidney injury.

Frazier Healthcare Partners led the round with participation from Longitude Capital, existing investor Euclidean Capital and an undisclosed investor...